3-(3-biphenylyl)propanal | 136415-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-biphenylyl)propanal
• 英文别名: 3-(1,1'-biphenyl-3-yl)propanal；3-(3-phenylphenyl)propanal
• CAS: 136415-88-8
• 化学式: C₁₅H₁₄O
• 分子量: 210.276
• InChiKey: JCFUBJSIMQRJLI-UHFFFAOYSA-N

物化性质

• 沸点：
  337.5±11.0 °C(Predicted)
• 密度：
  1.044±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-biphenylyl)propanal 在 2,6-二甲基吡啶 、 potassium tert-butylate 、 溶剂黄146 、 锌 、 三氯氧磷 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 33.5h， 生成 [3-(2-Biphenyl-3-yl-ethyl)-cyclobut-1-enyloxy]-tert-butyl-dimethyl-silane
  参考文献：
  名称：

  Synthesis and Biological Activities of New HMG-CoA Synthase Inhibitors: 2-Oxetanones with a Side Chain Containing Biphenyl, Terphenyl or Phenylpyridine

  摘要：

  A series of 1233A analogs containing biphenylyl, terphenylyl or phenylpyridyl groups in their side chain were synthesized and tested for the inhibitory activities against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and inhibition for the cholesterol biosynthesis in the mouse liver. The compounds with an oxetane, cyclobutanone or gamma-butyrolactone ring as isosters of a 2-oxetanone ring were entirely inactive. Among sythetic analogs, anti-4-[3-[2-(5-isopropyl-2-pyridyl)-ethyl]-phenyl]ethyl]-3-hydroxymethyl-2-oxetanone (10b) was most active in vitro. The structure-activity relationships on the transformations of 2-oxetanone and its side chain were obtained.

  DOI：

  10.3987/com-94-6720
• 作为产物：
  描述：

  3-(3-苯基苯基)丙酸甲酯 在 lithium aluminium tetrahydride 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 乙醚 为溶剂， 反应 1.5h， 生成 3-(3-biphenylyl)propanal
  参考文献：
  名称：

  Synthesis and Biological Activity of New 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Synthase Inhibitors: 2-Oxetanones with a Side Chain Mimicking the Folded Structure of 1233A.

  摘要：

  为模拟1233A（1）的折叠侧链构象，该化合物是一种3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）合酶抑制剂，合成了侧链含有芳环的1233A类似物。其中2-恶坦酮部分保持不变。在1233A及其合成类似物中，反式-3-羟甲基-4-[2-(7-甲氧羰基-1-萘基)乙基]-2-恶坦酮（23）显示了最高的HMG-CoA合酶体外抑制活性。讨论了侧链上的构效关系。

  DOI：

  10.1248/cpb.42.512

文献信息

• PHENYL BIPHENYLPYRIMIDINE COMPOUND AND AN ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
  申请人：E-RAY OPTOELECTRONICS TECHNOLOGY CO., LTD.

  公开号：US20200127211A1

  公开（公告）日：2020-04-23

  The present disclosure provides phenyl biphenylpyrimidine compounds of formula (I) and an organic electroluminescent device using the same: wherein X1 and A1 each independently represents substituted or unsubstituted C6-30 aryl or substituted or unsubstituted C5-30 heteroaryl having at least one heteroatom selected from the group consisting of N, O, and S, and n represents an integer of 1 or 2.

  本公开提供了公式（I）的苯基联苯嘧啶化合物以及使用这些化合物的有机电致发光器件： 其中X1和A1分别独立表示取代或未取代的C6-30芳基或取代或未取代的C5-30杂芳基，其中至少有一个杂原子选自N、O和S组成，n表示1或2的整数。
• PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE
  申请人：Burke, JR. Terrence R.

  公开号：US20120065146A1

  公开（公告）日：2012-03-15

  Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament.

  在各种真核生物中发现的波罗样激酶（Plks）是一类保守的Ser / Thr蛋白激酶亚家族，它们在细胞增殖中发挥关键作用。本文提供了特异性抑制Plks，特别是Plk1活性的化合物。本文还提供了使用这些化合物治疗高增殖性疾病，特别是癌症的方法。此外，还提供了使用这些化合物制备药物的用途。
• [EN] 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID<br/>[FR] ACIDE 2,5-BISUBSTITUE 3-MERCAPTOPENTANOIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2003106420A1

  公开（公告）日：2003-12-24

  The present invention concerns compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases where inhibition of carboxypeptidase U is beneficial. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式(I)的化合物以及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可以用于预防和治疗抑制羧肽酶U有益的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这些新化合物的过程；含有本发明化合物中至少一种，或其药学上可接受的盐或溶剂的制药组合物作为活性成分；以及将活性化合物用于制造上述医疗用途的药物。
• [EN] EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'ACIDES AMINES EXCITATEURS
  申请人：ELI LILLY AND COMPANY

  公开号：WO1996007405A1

  公开（公告）日：1996-03-14

  (EN) The present invention provides compounds of formula (I) in which R is as defined in the specification, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.(FR) Cette invention concerne des composés de formule (I), dans laquelle R est tel que défini dans le descriptif, ou un ester ou amide pharmaceutiquement acceptable de ces composés qui est métaboliquement labile, ou encore un sel pharmaceutiquement acceptable de ces composés, qu'on utilise comme antagonistes d'une ou de plusieurs actions du L-glutamate au niveau des récepteurs d'acides aminés excitateurs métabotropiques.

  本发明提供了公式（I）的化合物，其中R如规范中定义，或其药物可接受的代谢易裂解酯或酰胺，或其药物可接受的盐，这些化合物是L-谷氨酸在代谢型兴奋性氨基酸受体上的一个或多个作用的拮抗剂。
• 2,5-disubstituted 3-mercaptopentanoic acid
  申请人：Polla Magnus

  公开号：US20050176780A1

  公开（公告）日：2005-08-11

  The present invention concerns compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases where inhibition of carboxypeptidase U is beneficial. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式（I）的化合物，以及其药学上可接受的盐或溶剂，或该类盐的溶剂，这些化合物能够抑制羧肽酶U，因此可用于预防和治疗抑制羧肽酶U有益的疾病。在进一步方面，本发明涉及该发明的化合物用于治疗的用途；制备这种新化合物的过程；包含至少一种该发明化合物或其药学上可接受的盐或溶剂的药物组合物，作为活性成分；以及在制造上述医疗用途的药物中使用活性化合物。